Abstract
1YOPHILIZED factor VIII concentrates have beJ come the treatment of choice for factor VIII-deficient patients with hemophilia. The cost of such treatment is high, primarily because under normal conditions of collection and preparation, factor VIII procoagulant activity (VIIIC, sec Table 1 for terms and definitions1) is unstable and as much as 80 per cent of the activity is lost during the purification procedure. Recently, we have reported that factor VIIIC activity is stabilized when blood is collected into heparin rather than citrate anticoagulant, and we have shown that the cryoprecipitates obtained from heparinized blood contain 80 per cent of the VIIIC . . .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
